Mark Stein, MD, explores managing mHSPC through PSMA PET imaging, tumor burden assessment, and AMPLITUDE trial data while considering clinical context. The widespread adoption of PSMA PET imaging has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results